Industry News
Biotechnology Industry News
GSK has paid $50 million upfront…
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
As the biopharma world…
As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening of a new Gateway Labs site, this time in Philadelphia.
Clinical trials succeed or stall…
Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. The science of the trial may be sound and the protocol may be innovative, but
On its face, there wasn’t much…
On its face, there wasn’t much notable about Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio). A $1.15 billion upfront payment to secure a phase 3-ready monoclonal antibody is chump change in the broader
Vanda Pharmaceuticals’ expansion…
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing up to start a phase
This year saw attendance jump…
This year saw attendance jump again, with an estimated 4,500 people from 50 countries and across 950 healthcare companies set to show up.
Roche has reported another phase 3…
Roche has reported another phase 3 win for its oral selective estrogen receptor degrader. Success at a planned interim analysis positions giredestrant for use in the adjuvant setting, setting the Swiss drugmaker up to target
When Tim Hunt was invited to a…
When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services secretary had only been sworn in a few weeks earlier.
Single-use technologies (SUT) are…
Single-use technologies (SUT) are well-suited for modular production environments and represent a valuable solution in today’s ever-evolving biologics development landscape.
Genmab has shed another…
Genmab has shed another antibody-drug conjugate from its April 2024 acquisition of ProfoundBio. The Danish pharma has dropped development of GEN1160, a company spokesperson confirmed to Fierce Biotech, halting a phase 1/2 trial of the
After laying off most of its staff…
After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech XenoTherapeutics.
Bayer has built a home for Chinese…
Bayer has built a home for Chinese biopharma companies. Located in Beijing, the Bayer E-Town Open Innovation Center will incubate local biotechs starting with Suzhou Puhe BioPharma and Beijing Youngen Technology.
At the center of the acquisition…
At the center of the acquisition is Halda’s “hold and kill” bifunctional small molecule platform and a lead candidate in prostate cancer.
Cytokinetics may be counting down…
Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficatem. But for a biotech planning to commercialize its first drug—and without Big Pharma backing—the company's CEO Robert
Nxera Pharma has outlined plans to…
Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.
Nuvalent has reported phase 1/2…
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
A San Diego biotech has set out to…
A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts.
The biotech will use the funds to…
The biotech will use the funds to extend its clinical ambitions for its pipeline of DNA-damage-response-inhibiting cancer prospects.
After touting an impressive 1…
After touting an impressive 1 billion-euro-plus fundraising haul back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.
After already halving its…
After already halving its workforce twice since 2022, Sensei Therapeutics is forging ahead with another deep round of cuts.